Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel Free CMND Stock Alerts

Clearmind Medicine (CMND) Competitors

Clearmind Medicine logo
$2.26 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$2.26 +0.01 (+0.22%)
As of 05/22/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CMND vs. ALBT, SNGX, SPRC, ENSC, and MYNZ

Should you buy Clearmind Medicine stock or one of its competitors? MarketBeat compares Clearmind Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clearmind Medicine include Avalon GloboCare (ALBT), Soligenix (SNGX), SciSparc (SPRC), Ensysce Biosciences (ENSC), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.

How does Clearmind Medicine compare to Avalon GloboCare?

Clearmind Medicine (NASDAQ:CMND) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avalon GloboCare
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Clearmind Medicine has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Avalon GloboCare's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
Avalon GloboCare N/A N/A -74.36%

Clearmind Medicine has higher earnings, but lower revenue than Avalon GloboCare. Clearmind Medicine is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
Avalon GloboCare$1.26M3.68-$18.26M-$3.51N/A

In the previous week, Clearmind Medicine had 8 more articles in the media than Avalon GloboCare. MarketBeat recorded 8 mentions for Clearmind Medicine and 0 mentions for Avalon GloboCare. Clearmind Medicine's average media sentiment score of 0.24 beat Avalon GloboCare's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Neutral
Avalon GloboCare Neutral

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Avalon GloboCare beats Clearmind Medicine on 7 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Soligenix?

Clearmind Medicine (NASDAQ:CMND) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Clearmind Medicine's return on equity of -207.53% beat Soligenix's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
Soligenix N/A -244.73%-131.22%

In the previous week, Clearmind Medicine had 2 more articles in the media than Soligenix. MarketBeat recorded 8 mentions for Clearmind Medicine and 6 mentions for Soligenix. Soligenix's average media sentiment score of 1.00 beat Clearmind Medicine's score of 0.24 indicating that Soligenix is being referred to more favorably in the news media.

Company Overall Sentiment
Clearmind Medicine Neutral
Soligenix Positive

Clearmind Medicine has higher earnings, but lower revenue than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
Soligenix$120K48.18-$11.08M-$1.68N/A

Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,438.07%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Soligenix
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Clearmind Medicine has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Soligenix has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Soligenix beats Clearmind Medicine on 8 of the 14 factors compared between the two stocks.

How does Clearmind Medicine compare to SciSparc?

Clearmind Medicine (NASDAQ:CMND) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Clearmind Medicine has higher earnings, but lower revenue than SciSparc.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
SciSparc$860K2.83-$12.18MN/AN/A

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SciSparc's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
SciSparc N/A N/A N/A

In the previous week, Clearmind Medicine had 7 more articles in the media than SciSparc. MarketBeat recorded 8 mentions for Clearmind Medicine and 1 mentions for SciSparc. Clearmind Medicine's average media sentiment score of 0.24 beat SciSparc's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SciSparc
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
SciSparc
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

Summary

SciSparc beats Clearmind Medicine on 6 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Ensysce Biosciences?

Clearmind Medicine (NASDAQ:CMND) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ensysce Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Clearmind Medicine has higher earnings, but lower revenue than Ensysce Biosciences. Clearmind Medicine is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
Ensysce Biosciences$5.07M0.92-$10.18M-$3.35N/A

Clearmind Medicine has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

In the previous week, Clearmind Medicine had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 8 mentions for Clearmind Medicine and 6 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.71 beat Clearmind Medicine's score of 0.24 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ensysce Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Clearmind Medicine has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Clearmind Medicine's return on equity of -207.53% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
Ensysce Biosciences -250.39%-766.45%-256.59%

Summary

Clearmind Medicine and Ensysce Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Mainz Biomed's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
Clearmind Medicine N/A -207.53%-100.70%

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Clearmind Medicine has lower revenue, but higher earnings than Mainz Biomed. Clearmind Medicine is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$659.94K45.72-$21.65M-$65.60N/A
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A

96.1% of Clearmind Medicine shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Clearmind Medicine had 8 more articles in the media than Mainz Biomed. MarketBeat recorded 8 mentions for Clearmind Medicine and 0 mentions for Mainz Biomed. Clearmind Medicine's average media sentiment score of 0.24 beat Mainz Biomed's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Mainz Biomed Neutral
Clearmind Medicine Neutral

Summary

Mainz Biomed and Clearmind Medicine tied by winning 6 of the 12 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMND vs. The Competition

Export
MetricClearmind MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.30M$3.04B$6.46B$12.34B
Dividend YieldN/A1.97%2.76%5.28%
P/E Ratio-0.1117.7920.9925.66
Price / SalesN/A336.21560.3086.31
Price / CashN/A57.7443.4956.67
Price / Book0.165.8610.417.14
Net Income-$3.86M$74.99M$3.57B$335.98M
7 Day Performance-4.36%3.11%6.41%4.15%
1 Month Performance-72.16%-3.05%3.55%2.54%
1 Year Performance-99.41%34.38%34.12%35.06%

Clearmind Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
1.1493 of 5 stars		$2.26
flat		N/A-99.4%$2.30MN/AN/AN/A
ALBT
Avalon GloboCare
0.3753 of 5 stars		$0.32
-17.9%		N/A-89.8%$3.24M$1.26MN/A5
SNGX
Soligenix
2.1196 of 5 stars		$0.36
+17.1%		$6.00
+1,553.8%		-78.4%$3.19M$120KN/A20
SPRC
SciSparc
0.0933 of 5 stars		$5.02
-7.6%		N/A-92.7%$3.07M$860KN/A4
ENSC
Ensysce Biosciences
1.2681 of 5 stars		$0.29
-8.9%		N/A-85.5%$2.94M$5.07MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel